Press Latest Release http://www.csl.com.au CSL News Wed, 12 Apr 2017 00:00:00 -0500 CSL Response to Patent Complaint thumbnail CSL remains highly confident that CSL830 does not infringe any valid claim of the Shire ViroPharma patent and will vigorously defend against the claims.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252904542423/prdetail.htm 1252904542423 Wed, 15 Feb 2017 00:00:00 -0500 Half Year Result 20171 thumbnail CSL Limited (ASX:CSL; USOTC:CSLLY) today announced a net profit after tax (NPAT) of $806 million for the six months ended 31 December 2016, up $87 million or 12% on a reported basis when compared to the prior comparable period (PCP).   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252904041419/prdetail.htm 1252904041419 Fri, 10 Feb 2017 00:00:00 -0500 Study Published in Cell Metabolism shows Potential New Therapy for Diabetic Kidney Disease thumbnail Melbourne, 10 February, 2017 04.00AM AEDT: An international team of scientists in collaboration with global biotechnology leader CSL has successfully prevented the progression of Diabetic Kidney Disease (DKD) in laboratory studies of type 2 diabetes.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252904056688/prdetail.htm 1252904056688 Thu, 19 Jan 2017 09:00:00 -0500 FY2017 profit upgrade thumbnail CSL Limited (ASX:CSL; USOTC:CSLLY) today upgraded its net profit after tax (NPAT) expectation for FY2017. Following strong sales performance, CSL expects to report NPAT of approximately US$800 million for the six months ended 31 December 2016.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252903872987/prdetail.htm 1252903872987 Thu, 05 Jan 2017 00:00:00 -0500 Momenta and CSL Announce Collaboration and License Agreement to Develop Fc Multimer Programs, Including M230, a Selective Immunomodulator of Fc Receptors thumbnail Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) and CSL Limited (ASX:CSL; USOTC:CSLLY) today announced that they have entered into an exclusive research collaboration and worldwide license agreement to develop and commercialize Fc multimer proteins, including Momenta’s M230, a selective immunomodulator of Fc receptors, which is expected to enter the clinic in 2017.   http://www.csl.com.au/s1/cs/auhq/1187378853299/news/1252903829512/prdetail.htm 1252903829512